{"ticker": {"uuid": "8bed94f3-3583-428e-8c2b-98c0e08bd4af", "symbol": "ARCT", "name": "Arcturus Therapeutics Holdings Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOMzFGa3N5RlA1Qm9KRG5RQ3Bxd1J2TE9ZdndQYWRuem5RejUtRGM2RGpGNm42QkkwcEpjSEhCbnVkNWhXVy0zd3FRaGpQOFB0UkRtUFE3S2NRZlhQUWlyOWI0YXhlcGg0TWhKVjV3UTJoSDNyWmhVYmp1YV9OcDV6VExzNjNocWpVRzZmYks1TDJNTmpITDczcUVKYm8wR3otelVwU0lUSURwcldiX3FaeExBcjBBUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T04:55:26+00:00", "published_display": "15 Jul 2026 04:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis", "summary": "Arcturus Therapeutics (ARCT) is gaining attention for its inhaled mRNA therapeutic, ARCT-032, for cystic fibrosis, which is advancing to a pivotal Phase 2 study after promising early safety and mucus reduction data. The company has a robust mRNA platform, including self-amplifyin", "url": "https://www.kavout.com/market-lens/is-arcturus-therapeutics-arct-032-a-game-changer-for-cystic-fibrosis", "source_name": "Kavout | AI", "published_at": "2026-07-12T00:40:48", "published_display": "12 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Should I Buy", "summary": "This article analyzes whether Arcturus Therapeutics Holdings Inc (ARCT) is a good investment, concluding with a \"Hold\" recommendation for beginner long-term investors. While the stock benefits from supportive analyst coverage and a promising Thermo Fisher collaboration, its curre", "url": "https://intellectia.ai/en/stock/ARCT/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-07-11T01:41:11", "published_display": "11 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Q1 2025 earnings summary", "summary": "Arcturus Therapeutics (ARCT) reported its Q1 2025 earnings, highlighting a prioritized mRNA therapeutics pipeline focused on cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs. The company achieved EU and Japan approvals for KOSTAIVE\u00ae, its self-amplifyi", "url": "https://quartr.com/events/arcturus-therapeutics-holdings-inc-arct-q1-2025_ondoz0ri", "source_name": "Quartr", "published_at": "2026-07-09T01:45:48", "published_display": "09 Jul 2026 01:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23", "summary": "BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target of $23. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72517856/btig-maintains-arcturus-therapeutics-arctus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-06T23:17:10", "published_display": "06 Jul 2026 23:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Arcturus Therapeutics Holdings Inc. \u2013 NASDAQ:ARCT", "summary": "This page displays the \"Price to sales forward\" metric for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). It indicates that the market for ARCT was closed and no trades were recorded, providing various financial, news, and community tabs for further research.", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T22:40:15", "published_display": "04 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Arcturus Therape (ARCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBNMV9sSkU3cVZtUnpFWVZOSUNkSXRWOWd0U1RxeGUya1dieGZkWGhfWnhONUcyaUhhWkVXNzFiNUF3dDdubUtuX1Y0TndNUkhwbjY3dXlPM0tOYlU0ekJNNWhsUmp6MXJOWW9zX1F3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-04T07:30:44+00:00", "published_display": "04 Jul 2026 07:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial", "summary": "Thermo Fisher Scientific has teamed up with Arcturus Therapeutics to advance ARCT-032, an investigational mRNA therapy for cystic fibrosis, into Phase III clinical trials. This collaboration will leverage Thermo Fisher's Accelerator Drug Development solutions for integrated manuf", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-arcturus-partner-phase-083155067.html", "source_name": "Market source", "published_at": "2026-07-03T16:31:00", "published_display": "03 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?", "summary": "Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-t", "url": "https://finance.yahoo.com/markets/stocks/articles/arcturus-therapeutics-arct-stock-jumps-110600231.html", "source_name": "Market source", "published_at": "2026-07-03T10:41:09", "published_display": "03 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis", "summary": "Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator\u2122 Drug Development solutions for integrated manufacturing,", "url": "https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-announces-strategic-collaboration-110000280.html", "source_name": "Market source", "published_at": "2026-07-03T10:41:08", "published_display": "03 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy", "summary": "Freedom Broker has initiated coverage on Arcturus Therapeutics (ARCT) with a \"Buy\" rating and a price target of $27.00. Despite this positive analyst outlook, GuruFocus assesses ARCT as 65.8% overvalued with a GF Value\u2122 of $4.15 compared to its current market price of $6.88. The ", "url": "https://www.gurufocus.com/news/8942723/arct-initiates-coverage-by-freedom-broker-rating-set-to-buy?mobile=true%3Fmobile%3Dtrue", "source_name": "GuruFocus", "published_at": "2026-07-02T17:11:37", "published_display": "02 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27", "summary": "Freedom Capital Markets has initiated coverage on Arcturus Therapeutics (ARCT.US) with a Buy rating. The firm has set a target price of $27 for the biotechnology company. This initiation suggests a positive outlook on Arcturus Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72390341/freedom-capital-markets-initiates-arcturus-therapeutics-arctus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-02T13:11:37", "published_display": "02 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-thermo-fisher-scientific-113320205.html", "source_name": "MT Newswires", "published_at": "2026-07-02T11:33:20+00:00", "published_display": "02 Jul 2026 11:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT - Arcturus Therapeutics Holdings Inc Latest SEC Filings", "summary": "This article provides key financial data and performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT), including its market capitalization, income, sales, per-share values, and various ratios. It also details the company's past and projected EPS and sales growth, inside", "url": "https://finviz.com/stock?t=ARCT&ta=1&p=m&ty=lf&b=2&r=max&page=6", "source_name": "Finviz", "published_at": "2026-07-02T09:40:05", "published_display": "02 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus taps Thermo Fisher to make its cystic fibrosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZEpxa3BvcWpkb0Ixelk4bHdHcm9UQVhnVENrZE05WENINUpwbGlOcGwxSWd6NnNVSHc1ZmZrOGZHQlhtRTdxbUc5YUdKaE1wVTBNSGFEVndBdG02emwwMWhnOFp2b1RFUVFfWmVqVERaNVNqSE5mT1FVVnZrTUNqdXdNUnhuajZQZkx3WHMxNHFyVjh5ME5jVTEyeE83OFJnTTVUZFFhT2g0RVlueFpYTm1ZZmNwOS1SWm9VNkt2RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9GRF9Uc0ROdF9CTWhoS3V3MGp6b2FDUjV3TVlBUjBUMzhDMXc4ZDF5akJhYlZubHVGOFVwWHRwMXJTYVpMZXpRakNkRWwwVG9NYWZJRDByREQtQXZ6N094UjNscXFuam41VHRaUnh0a2dSOEpHLThRbC1pVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Arcturus Therapeutics Holdings Inc. \u2013 NASDAQ:ARCT", "summary": "The article presents a financial data point for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a data visualization page from TradingView, indicating a value for this metric over", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:09:16", "published_display": "01 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark", "summary": "Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT) has been removed from the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This news follows several other recent benchmark removals for the company, including from the Russell Small Cap Comp Growth, Russell 2000 Gr", "url": "https://www.marketscreener.com/news/arcturus-therapeutics-holdings-inc-nasdaqgm-arct-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80fe26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:09:16", "published_display": "29 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT)", "summary": "This article provides an overview of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes key financial metrics such as market capitalization, EBITDA, and recent earnings r", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T00:12:26", "published_display": "26 Jun 2026 00:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Arcturus Therapeutics Holdings Inc. (ARCT) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:38", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ARCT Response", "summary": "This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting a near-term strong sentiment potentially challenging persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and offers three distinct trading str", "url": "https://news.stocktradersdaily.com/news_release/91/Discipline_and_Rules-Based_Execution_in_ARCT_Response_062126043602_1782030962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T04:39:00", "published_display": "21 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Arcturus Therapeutics Holdings Inc (ARCT) currently holds a risk assessment score of 2.19, ranking 233 out of 389 in the Biotechnology & Medical Research industry. The company's beta value of 2.37 suggests higher volatility compared to the S&P 500. The assessment includes detaile", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:42", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms", "summary": "This page provides comprehensive access to Arcturus Therapeutics (ARCT) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading information. It details a recent Q2 2025 earnings press release and a Schedule 13G/A filing from ARK Investment Management disclosi", "url": "https://www.stocktitan.net/sec-filings/ARCT/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing major shareholders and their proportional holdings, including Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc", "summary": "This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that relevant data regarding the company's revenue breakdown by business segments and regional contribution have not been dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Arcturus Therapeutics Holdings Inc (ARCT), noting its current valuation score is 7.25, ranking 253 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.60, which is significantly bel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T03:09:10", "published_display": "17 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arcturus Therapeutics Holdings Inc (ARCT) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry, with an average analyst price target of $21.50. Analysts predominantly recommend a \"Buy\" for ARCT, with 12 analysts contributing to the rating. The company's ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T12:39:25", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30", "summary": "Arcturus Therapeutics Holdings Inc. director John Markels was granted 15,000 stock options at an exercise price of $7.30 per share as part of his 2026 annual board compensation. These options, which expire on June 5, 2036, will vest monthly over one year from the grant date. Foll", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-98dbef489056.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:07", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant", "summary": "Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options as part of his annual board compensation for 2026. These options, with an exercise price of $7.30 per share and an expiration date of June 5, 2036, will vest monthly over one year from the", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-dd184fd3405e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:39:25", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Magda Marquet was granted 15,000 stock options with an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year and represent her 2026 annual grant as a Board member. The transaction indicat", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-aff1144b14aa.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:09:51", "published_display": "16 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant", "summary": "Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of 15,000 stock options as part of his 2026 annual board compensation. The options allow him to buy common stock at an exercise price of $7.30 per share and expire on June 5, 2036. These options will v", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-9da011d38ec8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options at an exercise price of $7.30 per share, expiring on June 5, 2036. This grant represents her 2026 annual compensation for Board service, with the options vesting monthly over one year fr", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-933dbfecc876.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Peter C. Farrell has been granted 15,000 stock options as part of his 2026 annual compensation for Board service. The options have an exercise price of $7.3000 per share, expire on June 5, 2036, and will vest monthly over one year from", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-bf8a49b9e2b6.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant", "summary": "Arcturus Therapeutics Inc. director James F. Barlow was granted 15,000 stock options as part of his 2026 board compensation. These options allow him to buy common stock at an exercise price of $7.30 per share and will vest monthly over a one-year period, aligning his compensation", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-e7a00a9348c4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Key Developments Shaping mRNA Therapeutics Beyond COVID-19 Vaccines", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR3NNdEJaRGZQUVhxVGw3bnNiUVlMLUdabEYwaTAxTzlMY2w1eW45VlBNYXJETGF6Vl9XNVJyOFd4LTYxcGpXMUVEMUdmWkIxS29yeXZEX3ByX1A2UjJ4SGRJSHdHLXBtRVRrel9KQ0FQLWdKMmoxUWFuVEhmWGZ0STNPNS0wS0RkZFNKeXptR0hEUVY4S3ZRUVRqdDZ5cnU4MmtGanFMaw?oc=5", "source_name": "BioPharm International", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies", "summary": "Arcturus Therapeutics presented its mRNA pipeline, including vaccine approvals and clinical milestones, at the Jefferies Global Healthcare Conference. The company emphasized its differentiated LUNAR delivery platform and manufacturing capabilities for therapeutic mRNA application", "url": "https://www.tradingview.com/news/marketbeat:5c5bd77db094b:0-arcturus-therapeutics-highlights-mrna-pipeline-cf-data-and-vaccine-expansion-at-jefferies/", "source_name": "TradingView", "published_at": "2026-06-05T23:39:42", "published_display": "05 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/1ef26c64-1824-3b2e-b053-b54878cb59e5/arcturus-therapeutics.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings (ARCT) Q4 Loss Deepens To US$1.03 EPS Challenging Profitability Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/f6630ed4-d9dd-3998-873d-9254db32bae4/arcturus-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-07T21:39:35+00:00", "published_display": "07 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbHZja0RlUjBkbmFTbFVWTHAxNzZHRlFteFpEQUd3T3l4X2dkMTNfVnJNcUdIVVBMQkdzZXd6YkMwM2w3RlAyZmxMQm04OWVqck5hcGRXUXh2R0x0Y3RJNDI3V3hGc2dmOVVMMlRhYk1vSnVsQ2h0Rm1wc1JHTXRCRi1OWFJBd0RWaHZweG5hQVFrcFlwc2RzMmpoMmVBa3FoTDlOMEJaZHhEUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Report Preview: What To Expect", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcturus-therapeutics-holdings-inc-arct-133323048.html", "source_name": "GuruFocus.com", "published_at": "2026-05-06T13:33:23+00:00", "published_display": "06 May 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arcturus Therapeutics Stock Plunges Over 58% Today: What\u2019s Causing The Sell-Off?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQUhMODFFR0d1UlFKYUg2aGhXSG5DVXQwZ2R2Ylc3RWlNZUo3c2xzQkZjb3RUZnVFNjlGVjQ5Q0JrdHEwS043cmItV3RPeEg0YjVCdG4wUTNkYzdHa1oycUpZT1duSEtPZUlDNFZaMzBJcWVCeGhYQW9ZbFNid0VHTlFpdHhkZm5SWTA5dC1peGctd2RWdWw5bGJGRXI1ZDdM?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcVV3NUY2TmlHUXluZ1BFclo4QUozUUFQcFVLb1RhRFgyenl4QTFaODVwNmw2MkM1UWl3OENQbURENGJnUUU4UV9JZHlGUmtTeVBucE0zTWVTN1NKdGxMT2xwNWRncDh6aEdoZ0xZaklPVURIOGZ4Rm5INndLM3VPWVpVYlNTOHlyZ3kwSXk3X1VxV3lyazl5VklYMDY2cnNHWXcyYS1hNTJGS1JwbjZrUTFfZTNUX2luRjE4dlgzTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics Poised for a Massive Upside in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeHdTZGFjTEt1RDlDQjFNQ24wdG4wRFZDLTYweVBPTzdfQk5SY2xQb2pWZWY3d1VtTXB1MFVTT2JLSnJrSWhLbGxMclltY3VVdjdYMlZaa0lhekd4bE9ib2J2emRKaHRxZER5bnd5UF9iSVZQR1V1YWpmdll5M3BxX2xneDRJNEFLRUZ2YkQtNE85QXZyVlR2cnhvSQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-01T05:50:06+00:00", "published_display": "01 Mar 2026 05:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOZ0NxTDU2MFVDYnN4TGE5anZGd3p1eFhJR2pfa3hMY19ON3RLUXo2VmY2WDAzQ2c1S25FMGgySlBZc1pTdm95Rm1Janc0LTRSNHVUYU4tamswb1dTU1lzbUo2cS0xOG1NM1c3OVN1dzc3UTZ0c0h5enl2WGtJOE9lM3FLdGJUdkRpYU43SXZIX3Y5NnNja1laanBuQ0lqQ1ZxS200SG55VFI5UWhyQ3AxOXZucXpIN3VUSjdDSGJ3SlZ5MExQaUcxUXRtXzE2RTYtTmZydzZFM216M3lHM2ViLTFlaUNxemVwdnY4?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNRUtiSldEbndNUzFjZkNxbEhOX1N5Mld1RzFwNEh5a2FNdzJqSTEwRVBvbjQ0MV9CcDdmeXZwdGFLNGFhRUs1ZHJvaUh4eHUxYjdQNHZST3JVRGdnWklaV0w1TEFvSGludlhrR2RUVUQtLXdKWk9hYUxGU2hNNnp0V0VGUnhYQ1d2cVE2OHc3Z0NSUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMS0tTUxYdFJfYjVBbG8tOWlGSERIakNJc29qZkZMTkZERnRHZURmM05rYzBUSmhabVgwLU5BNmNTMWZfTXoyajNlVFY1NDRyZ01uRzJ0RzRqVWRNN0lUZFM4bGpMWGV1djc5SERHa1c2b2o1TzNfcGx4U3UySEVwNHZfLVMtWXVI?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQcGlQck03b1o1NEVoNHF5YVpEOGZnTlhHcGdtdlJNUS1uVTRWVUJnS1d6OHd4Ym5LWTRRMkRoYkFITmVDODRpT3FHN3JVN3c2MXhpVkJVQXFDOXdROVBOR0ZNUzRUY3plT2F4V2lsMW5TbWk3M2NpME1XcmFyUTVYaTVOTjJQRUFpMWc?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNS2NnVHdmZ3pRMGpwX2taVV9rUVdFTUZpQ2N5LTRNLW5VbTlfYnp0cy1FZld1RzYxdi1EYjR0WnFyYTF1UlBDZk5XU1N6S1FBWXQwemFUdUhmb0NYdS0zUFk2cjMwUVdkcVgxTkExcVg0eXlhUmZyLXhrTDJVNDY3enAtN05uSkV2ZFZMTUJxc1A?oc=5", "source_name": "Market source", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOMzFGa3N5RlA1Qm9KRG5RQ3Bxd1J2TE9ZdndQYWRuem5RejUtRGM2RGpGNm42QkkwcEpjSEhCbnVkNWhXVy0zd3FRaGpQOFB0UkRtUFE3S2NRZlhQUWlyOWI0YXhlcGg0TWhKVjV3UTJoSDNyWmhVYmp1YV9OcDV6VExzNjNocWpVRzZmYks1TDJNTmpITDczcUVKYm8wR3otelVwU0lUSURwcldiX3FaeExBcjBBUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T04:55:26+00:00", "published_display": "15 Jul 2026 04:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis", "summary": "Arcturus Therapeutics (ARCT) is gaining attention for its inhaled mRNA therapeutic, ARCT-032, for cystic fibrosis, which is advancing to a pivotal Phase 2 study after promising early safety and mucus reduction data. The company has a robust mRNA platform, including self-amplifyin", "url": "https://www.kavout.com/market-lens/is-arcturus-therapeutics-arct-032-a-game-changer-for-cystic-fibrosis", "source_name": "Kavout | AI", "published_at": "2026-07-12T00:40:48", "published_display": "12 Jul 2026 00:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Should I Buy", "summary": "This article analyzes whether Arcturus Therapeutics Holdings Inc (ARCT) is a good investment, concluding with a \"Hold\" recommendation for beginner long-term investors. While the stock benefits from supportive analyst coverage and a promising Thermo Fisher collaboration, its curre", "url": "https://intellectia.ai/en/stock/ARCT/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-07-11T01:41:11", "published_display": "11 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Q1 2025 earnings summary", "summary": "Arcturus Therapeutics (ARCT) reported its Q1 2025 earnings, highlighting a prioritized mRNA therapeutics pipeline focused on cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency programs. The company achieved EU and Japan approvals for KOSTAIVE\u00ae, its self-amplifyi", "url": "https://quartr.com/events/arcturus-therapeutics-holdings-inc-arct-q1-2025_ondoz0ri", "source_name": "Quartr", "published_at": "2026-07-09T01:45:48", "published_display": "09 Jul 2026 01:45", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23", "summary": "BTIG has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) and maintained its price target of $23. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72517856/btig-maintains-arcturus-therapeutics-arctus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-06T23:17:10", "published_display": "06 Jul 2026 23:17", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Arcturus Therapeutics Holdings Inc. \u2013 NASDAQ:ARCT", "summary": "This page displays the \"Price to sales forward\" metric for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). It indicates that the market for ARCT was closed and no trades were recorded, providing various financial, news, and community tabs for further research.", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T22:40:15", "published_display": "04 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Arcturus Therape (ARCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBNMV9sSkU3cVZtUnpFWVZOSUNkSXRWOWd0U1RxeGUya1dieGZkWGhfWnhONUcyaUhhWkVXNzFiNUF3dDdubUtuX1Y0TndNUkhwbjY3dXlPM0tOYlU0ekJNNWhsUmp6MXJOWW9zX1F3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-04T07:30:44+00:00", "published_display": "04 Jul 2026 07:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trial", "summary": "Thermo Fisher Scientific has teamed up with Arcturus Therapeutics to advance ARCT-032, an investigational mRNA therapy for cystic fibrosis, into Phase III clinical trials. This collaboration will leverage Thermo Fisher's Accelerator Drug Development solutions for integrated manuf", "url": "https://finance.yahoo.com/healthcare/articles/thermo-fisher-arcturus-partner-phase-083155067.html", "source_name": "Market source", "published_at": "2026-07-03T16:31:00", "published_display": "03 Jul 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?", "summary": "Arcturus Therapeutics (ARCT) stock jumped 5.7% after the company announced a strategic collaboration with Thermo Fisher Scientific for the phase III development and commercialization of its cystic fibrosis mRNA therapy, ARCT-032. While the stock saw a significant gain, its near-t", "url": "https://finance.yahoo.com/markets/stocks/articles/arcturus-therapeutics-arct-stock-jumps-110600231.html", "source_name": "Market source", "published_at": "2026-07-03T10:41:09", "published_display": "03 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis", "summary": "Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational mRNA therapy, ARCT-032, for Cystic Fibrosis. This partnership will leverage Thermo Fisher's Accelerator\u2122 Drug Development solutions for integrated manufacturing,", "url": "https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-announces-strategic-collaboration-110000280.html", "source_name": "Market source", "published_at": "2026-07-03T10:41:08", "published_display": "03 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Initiates Coverage by Freedom Broker -- Rating Set to Buy", "summary": "Freedom Broker has initiated coverage on Arcturus Therapeutics (ARCT) with a \"Buy\" rating and a price target of $27.00. Despite this positive analyst outlook, GuruFocus assesses ARCT as 65.8% overvalued with a GF Value\u2122 of $4.15 compared to its current market price of $6.88. The ", "url": "https://www.gurufocus.com/news/8942723/arct-initiates-coverage-by-freedom-broker-rating-set-to-buy?mobile=true%3Fmobile%3Dtrue", "source_name": "GuruFocus", "published_at": "2026-07-02T17:11:37", "published_display": "02 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freedom Capital Markets Initiates Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $27", "summary": "Freedom Capital Markets has initiated coverage on Arcturus Therapeutics (ARCT.US) with a Buy rating. The firm has set a target price of $27 for the biotechnology company. This initiation suggests a positive outlook on Arcturus Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/72390341/freedom-capital-markets-initiates-arcturus-therapeutics-arctus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-07-02T13:11:37", "published_display": "02 Jul 2026 13:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arcturus-therapeutics-thermo-fisher-scientific-113320205.html", "source_name": "MT Newswires", "published_at": "2026-07-02T11:33:20+00:00", "published_display": "02 Jul 2026 11:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT - Arcturus Therapeutics Holdings Inc Latest SEC Filings", "summary": "This article provides key financial data and performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT), including its market capitalization, income, sales, per-share values, and various ratios. It also details the company's past and projected EPS and sales growth, inside", "url": "https://finviz.com/stock?t=ARCT&ta=1&p=m&ty=lf&b=2&r=max&page=6", "source_name": "Finviz", "published_at": "2026-07-02T09:40:05", "published_display": "02 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus taps Thermo Fisher to make its cystic fibrosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZEpxa3BvcWpkb0Ixelk4bHdHcm9UQVhnVENrZE05WENINUpwbGlOcGwxSWd6NnNVSHc1ZmZrOGZHQlhtRTdxbUc5YUdKaE1wVTBNSGFEVndBdG02emwwMWhnOFp2b1RFUVFfWmVqVERaNVNqSE5mT1FVVnZrTUNqdXdNUnhuajZQZkx3WHMxNHFyVjh5ME5jVTEyeE83OFJnTTVUZFFhT2g0RVlueFpYTm1ZZmNwOS1SWm9VNkt2RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus rises on pact with Thermo Fisher for cystic fibrosis therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9GRF9Uc0ROdF9CTWhoS3V3MGp6b2FDUjV3TVlBUjBUMzhDMXc4ZDF5akJhYlZubHVGOFVwWHRwMXJTYVpMZXpRakNkRWwwVG9NYWZJRDByREQtQXZ6N094UjNscXFuam41VHRaUnh0a2dSOEpHLThRbC1pVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Arcturus Therapeutics Holdings Inc. \u2013 NASDAQ:ARCT", "summary": "The article presents a financial data point for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) specifically focusing on its price-to-earnings forward ratio. The content appears to be a stub or a data visualization page from TradingView, indicating a value for this metric over", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T09:09:16", "published_display": "01 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark", "summary": "Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT) has been removed from the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This news follows several other recent benchmark removals for the company, including from the Russell Small Cap Comp Growth, Russell 2000 Gr", "url": "https://www.marketscreener.com/news/arcturus-therapeutics-holdings-inc-nasdaqgm-arct-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80fe26", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:09:16", "published_display": "29 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT)", "summary": "This article provides an overview of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes key financial metrics such as market capitalization, EBITDA, and recent earnings r", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-06-26T00:12:26", "published_display": "26 Jun 2026 00:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Arcturus Therapeutics Holdings Inc. (ARCT) stock for 2027, based on analyst opinions. It includes current stock performance, historical highs and lows, market capitalization, volatility, and details on past and upcoming earnin", "url": "https://www.tradingview.com/symbols/NASDAQ-ARCT/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:38", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ARCT Response", "summary": "This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, highlighting a near-term strong sentiment potentially challenging persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and offers three distinct trading str", "url": "https://news.stocktradersdaily.com/news_release/91/Discipline_and_Rules-Based_Execution_in_ARCT_Response_062126043602_1782030962.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T04:39:00", "published_display": "21 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Arcturus Therapeutics Holdings Inc (ARCT) currently holds a risk assessment score of 2.19, ranking 233 out of 389 in the Biotechnology & Medical Research industry. The company's beta value of 2.37 suggests higher volatility compared to the S&P 500. The assessment includes detaile", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-19T03:39:42", "published_display": "19 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARCT SEC Filings - Arcturus Therape 10-K, 10-Q, 8-K Forms", "summary": "This page provides comprehensive access to Arcturus Therapeutics (ARCT) SEC filings, including 10-K, 10-Q, and 8-K forms, along with insider trading information. It details a recent Q2 2025 earnings press release and a Schedule 13G/A filing from ARK Investment Management disclosi", "url": "https://www.stocktitan.net/sec-filings/ARCT/page-4.html", "source_name": "Stock Titan", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Arcturus Therapeutics Holdings Inc (ARCT), listing major shareholders and their proportional holdings, including Federated Hermes Global Investment Management Corp., ARK Investment Management LLC, and BlackRock Institutional Trust", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc", "summary": "This article provides an overview of Arcturus Therapeutics Holdings Inc (ARCT), including its current stock price and market capitalization. It highlights that relevant data regarding the company's revenue breakdown by business segments and regional contribution have not been dis", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T03:40:33", "published_display": "17 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Arcturus Therapeutics Holdings Inc (ARCT), noting its current valuation score is 7.25, ranking 253 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.60, which is significantly bel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T03:09:10", "published_display": "17 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arcturus Therapeutics Holdings Inc (ARCT) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry, with an average analyst price target of $21.50. Analysts predominantly recommend a \"Buy\" for ARCT, with 12 analysts contributing to the rating. The company's ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-arct/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T12:39:25", "published_display": "16 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30", "summary": "Arcturus Therapeutics Holdings Inc. director John Markels was granted 15,000 stock options at an exercise price of $7.30 per share as part of his 2026 annual board compensation. These options, which expire on June 5, 2036, will vest monthly over one year from the grant date. Foll", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-98dbef489056.html", "source_name": "Stock Titan", "published_at": "2026-06-16T04:10:07", "published_display": "16 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant", "summary": "Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options as part of his annual board compensation for 2026. These options, with an exercise price of $7.30 per share and an expiration date of June 5, 2036, will vest monthly over one year from the", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-dd184fd3405e.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:39:25", "published_display": "16 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Magda Marquet was granted 15,000 stock options with an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year and represent her 2026 annual grant as a Board member. The transaction indicat", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-aff1144b14aa.html", "source_name": "Stock Titan", "published_at": "2026-06-16T02:09:51", "published_display": "16 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant", "summary": "Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of 15,000 stock options as part of his 2026 annual board compensation. The options allow him to buy common stock at an exercise price of $7.30 per share and expire on June 5, 2036. These options will v", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-9da011d38ec8.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options at an exercise price of $7.30 per share, expiring on June 5, 2036. This grant represents her 2026 annual compensation for Board service, with the options vesting monthly over one year fr", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-933dbfecc876.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options", "summary": "Arcturus Therapeutics Holdings Inc. director Peter C. Farrell has been granted 15,000 stock options as part of his 2026 annual compensation for Board service. The options have an exercise price of $7.3000 per share, expire on June 5, 2036, and will vest monthly over one year from", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-bf8a49b9e2b6.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant", "summary": "Arcturus Therapeutics Inc. director James F. Barlow was granted 15,000 stock options as part of his 2026 board compensation. These options allow him to buy common stock at an exercise price of $7.30 per share and will vest monthly over a one-year period, aligning his compensation", "url": "https://www.stocktitan.net/sec-filings/ARCT/form-4-arcturus-therapeutics-holdings-inc-insider-trading-activity-e7a00a9348c4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T21:09:51", "published_display": "15 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6 Key Developments Shaping mRNA Therapeutics Beyond COVID-19 Vaccines", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR3NNdEJaRGZQUVhxVGw3bnNiUVlMLUdabEYwaTAxTzlMY2w1eW45VlBNYXJETGF6Vl9XNVJyOFd4LTYxcGpXMUVEMUdmWkIxS29yeXZEX3ByX1A2UjJ4SGRJSHdHLXBtRVRrel9KQ0FQLWdKMmoxUWFuVEhmWGZ0STNPNS0wS0RkZFNKeXptR0hEUVY4S3ZRUVRqdDZ5cnU4MmtGanFMaw?oc=5", "source_name": "BioPharm International", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies", "summary": "Arcturus Therapeutics presented its mRNA pipeline, including vaccine approvals and clinical milestones, at the Jefferies Global Healthcare Conference. The company emphasized its differentiated LUNAR delivery platform and manufacturing capabilities for therapeutic mRNA application", "url": "https://www.tradingview.com/news/marketbeat:5c5bd77db094b:0-arcturus-therapeutics-highlights-mrna-pipeline-cf-data-and-vaccine-expansion-at-jefferies/", "source_name": "TradingView", "published_at": "2026-06-05T23:39:42", "published_display": "05 Jun 2026 23:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/1ef26c64-1824-3b2e-b053-b54878cb59e5/arcturus-therapeutics.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings (ARCT) Q4 Loss Deepens To US$1.03 EPS Challenging Profitability Hopes", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/f6630ed4-d9dd-3998-873d-9254db32bae4/arcturus-therapeutics-q1.html", "source_name": "MarketBeat", "published_at": "2026-05-07T21:39:35+00:00", "published_display": "07 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbHZja0RlUjBkbmFTbFVWTHAxNzZHRlFteFpEQUd3T3l4X2dkMTNfVnJNcUdIVVBMQkdzZXd6YkMwM2w3RlAyZmxMQm04OWVqck5hcGRXUXh2R0x0Y3RJNDI3V3hGc2dmOVVMMlRhYk1vSnVsQ2h0Rm1wc1JHTXRCRi1OWFJBd0RWaHZweG5hQVFrcFlwc2RzMmpoMmVBa3FoTDlOMEJaZHhEUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings Inc (ARCT) Q1 2026 Earnings Report Preview: What To Expect", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arcturus-therapeutics-holdings-inc-arct-133323048.html", "source_name": "GuruFocus.com", "published_at": "2026-05-06T13:33:23+00:00", "published_display": "06 May 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Stock Plunges Over 58% Today: What\u2019s Causing The Sell-Off?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOQUhMODFFR0d1UlFKYUg2aGhXSG5DVXQwZ2R2Ylc3RWlNZUo3c2xzQkZjb3RUZnVFNjlGVjQ5Q0JrdHEwS043cmItV3RPeEg0YjVCdG4wUTNkYzdHa1oycUpZT1duSEtPZUlDNFZaMzBJcWVCeGhYQW9ZbFNid0VHTlFpdHhkZm5SWTA5dC1peGctd2RWdWw5bGJGRXI1ZDdM?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQcVV3NUY2TmlHUXluZ1BFclo4QUozUUFQcFVLb1RhRFgyenl4QTFaODVwNmw2MkM1UWl3OENQbURENGJnUUU4UV9JZHlGUmtTeVBucE0zTWVTN1NKdGxMT2xwNWRncDh6aEdoZ0xZaklPVURIOGZ4Rm5INndLM3VPWVpVYlNTOHlyZ3kwSXk3X1VxV3lyazl5VklYMDY2cnNHWXcyYS1hNTJGS1JwbjZrUTFfZTNUX2luRjE4dlgzTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics Poised for a Massive Upside in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPeHdTZGFjTEt1RDlDQjFNQ24wdG4wRFZDLTYweVBPTzdfQk5SY2xQb2pWZWY3d1VtTXB1MFVTT2JLSnJrSWhLbGxMclltY3VVdjdYMlZaa0lhekd4bE9ib2J2emRKaHRxZER5bnd5UF9iSVZQR1V1YWpmdll5M3BxX2xneDRJNEFLRUZ2YkQtNE85QXZyVlR2cnhvSQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-03-01T05:50:06+00:00", "published_display": "01 Mar 2026 05:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOZ0NxTDU2MFVDYnN4TGE5anZGd3p1eFhJR2pfa3hMY19ON3RLUXo2VmY2WDAzQ2c1S25FMGgySlBZc1pTdm95Rm1Janc0LTRSNHVUYU4tamswb1dTU1lzbUo2cS0xOG1NM1c3OVN1dzc3UTZ0c0h5enl2WGtJOE9lM3FLdGJUdkRpYU43SXZIX3Y5NnNja1laanBuQ0lqQ1ZxS200SG55VFI5UWhyQ3AxOXZucXpIN3VUSjdDSGJ3SlZ5MExQaUcxUXRtXzE2RTYtTmZydzZFM216M3lHM2ViLTFlaUNxemVwdnY4?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNRUtiSldEbndNUzFjZkNxbEhOX1N5Mld1RzFwNEh5a2FNdzJqSTEwRVBvbjQ0MV9CcDdmeXZwdGFLNGFhRUs1ZHJvaUh4eHUxYjdQNHZST3JVRGdnWklaV0w1TEFvSGludlhrR2RUVUQtLXdKWk9hYUxGU2hNNnp0V0VGUnhYQ1d2cVE2OHc3Z0NSUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNMS0tTUxYdFJfYjVBbG8tOWlGSERIakNJc29qZkZMTkZERnRHZURmM05rYzBUSmhabVgwLU5BNmNTMWZfTXoyajNlVFY1NDRyZ01uRzJ0RzRqVWRNN0lUZFM4bGpMWGV1djc5SERHa1c2b2o1TzNfcGx4U3UySEVwNHZfLVMtWXVI?oc=5", "source_name": "Market source", "published_at": "2026-02-02T08:00:00+00:00", "published_display": "02 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Arcturus Therapeutics (ARCT) JPM Conference Spotlight Clarify Its Long-Term Platform Credibility?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Arcturus Therapeutics (ARCT) Using Its $500 Million Shelf to Redefine Capital Strategy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQcGlQck03b1o1NEVoNHF5YVpEOGZnTlhHcGdtdlJNUS1uVTRWVUJnS1d6OHd4Ym5LWTRRMkRoYkFITmVDODRpT3FHN3JVN3c2MXhpVkJVQXFDOXdROVBOR0ZNUzRUY3plT2F4V2lsMW5TbWk3M2NpME1XcmFyUTVYaTVOTjJQRUFpMWc?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNS2NnVHdmZ3pRMGpwX2taVV9rUVdFTUZpQ2N5LTRNLW5VbTlfYnp0cy1FZld1RzYxdi1EYjR0WnFyYTF1UlBDZk5XU1N6S1FBWXQwemFUdUhmb0NYdS0zUFk2cjMwUVdkcVgxTkExcVg0eXlhUmZyLXhrTDJVNDY3enAtN05uSkV2ZFZMTUJxc1A?oc=5", "source_name": "Market source", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Revenues Yet As Shares Tumble 52%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 61, "sentiment_summary": {"positive": 16, "negative": 5, "neutral": 40, "score": 54, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 11.0, "count": 22}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 16, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.97, "latest_week": "2026-07-10", "one_week_move": -4.3, "four_week_move": 0.0, "twelve_week_move": -21.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.098012, "market_dynamics_buy_signal": false, "relative_strength": -43.051046, "fair_value_gap": -62.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.5299, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.3% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "TradingKey", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Kavout | AI", "count": 2}, {"label": "Intellectia AI", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 22}, {"label": "Analyst action", "count": 6}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.3% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20"}], "updated_at": "2026-07-16T06:05:19.414950+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}